{
  "$schema": "folio-library-entry/v1",
  "id": "10665-325892",
  "blocks": [
    {
      "id": "library/10665-325892/blocks/figure-img-p001-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 1,
      "pageEnd": 1,
      "target": "../images/img-p001-1.webp",
      "narrative": "draft",
      "content": "A photograph of a man in a blue T-shirt standing in a home and looking down at two small white medicine bottles in his hands. Behind him are floral and turquoise curtains and a television on a table covered with a red cloth.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-325892/blocks/prose-sec-front-matter",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Front matter",
      "pageStart": 1,
      "pageEnd": 2,
      "target": "../sections/sec-front-matter.md",
      "narrative": null,
      "content": "UPDATE OF \nRECOMMENDATIONS ON \nFIRST- AND SECOND-LINE \nANTIRETROVIRAL REGIMENS\nJULY 2019\nPOLICY BRIEF\nHIV TREATMENT",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The cover of the July 2019 WHO HIV treatment policy brief on updated recommendations for first- and second-line antiretroviral regimens.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-325892/blocks/prose-sec-000",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "WHO/CDS/HIV/19.15",
      "pageStart": 2,
      "pageEnd": 2,
      "target": "../sections/sec-000-whocdshiv1915.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-325892/blocks/prose-sec-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "© World Health Organization 2019",
      "pageStart": 2,
      "pageEnd": 3,
      "target": "../sections/sec-001-world-health-organization-2019.md",
      "narrative": null,
      "content": "Some rights reserved. This work is available under the Creative Commons Attribution-\nNonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/\nlicenses/by-nc-sa/3.0/igo). \nUnder the terms of this licence, you may copy, redistribute and adapt the work for non-commercial \npurposes, provided the work is appropriately cited, as indicated below. In any use of this work, there \nshould be no suggestion that WHO endorses any specific organization, products or services. The use \nof the WHO logo is not permitted. If you adapt the work, then you must license your work un",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The copyright and licensing page of the 2019 policy brief, setting out Creative Commons BY-NC-SA 3.0 IGO terms, citation and translation conditions, and standard WHO disclaimers. It also credits the cover photo and layout and notes printing in Switzerland.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-325892/blocks/prose-sec-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "BACKGROUND",
      "pageStart": 3,
      "pageEnd": 4,
      "target": "../sections/sec-002-background.md",
      "narrative": null,
      "content": "In 2018, WHO published interim guidelines recommending \ndolutegravir (DTG)-containing regimens as the preferred \nfirst- and second-line antiretroviral therapy (ART) regimens \nfor people living with HIV (1). However, a note of caution \nabout women of childbearing potential using DTG was issued \nfollowing a signal of a potential association of neural tube \ndefects and women’s use of DTG at the time of conception \nin an observational study from Botswana (2,3). These 2018 \nguidelines also recommended 400 mg of efavirenz (EFV), in \ncombination with tenofovir disoproxil fumarate (TDF) plus \nlamivudi",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains the background to the 2019 update: the 2018 interim guidance preferring dolutegravir (DTG) regimens, caution over a neural tube defect signal in Botswana, and gaps in evidence on efavirenz 400 mg. It then sets out the updated recommendations in a box, naming DTG-based regimens as preferred first- and second-line therapy, efavirenz 400 mg and raltegravir as alternatives, with strength and certainty ratings.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-325892/blocks/prose-sec-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "DTG IN FIRST-LINE ART",
      "pageStart": 4,
      "pageEnd": 4,
      "target": "../sections/sec-003-dtg-in-first-line-art.md",
      "narrative": null,
      "content": "An updated systematic review conducted in 2019 to support \nthe guidelines reaffirmed that a first-line regimen of DTG \ncombined with two nucleoside reverse-transcriptase inhibitors \n(NRTIs) leads to higher viral suppression and lower risk of \ndiscontinuing treatment and developing HIV drug resistance \ncompared with EFV-based regimens among treatment-\nnaive adults. DTG has other advantages over EFV, including \nlower potential for drug–drug interactions, more rapid viral \nsuppression and a higher genetic barrier to developing HIV \ndrug resistance (8,9). DTG is also active against HIV-2 \ninfectio",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Summarizes the 2019 systematic review showing DTG-based first-line therapy outperforms efavirenz on viral suppression, discontinuation and resistance, with fewer drug interactions and activity against HIV-2. It notes risks of sleep problems and weight gain and says women should receive information on benefits and risks of DTG at conception to make informed choices.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-325892/blocks/prose-sec-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "to women exposed to DTG before conception or early in pregnancy",
      "pageStart": 4,
      "pageEnd": 5,
      "target": "../sections/sec-004-to-women-exposed-to-dtg-before-conception-or-ear.md",
      "narrative": null,
      "content": "Although the prevalence of neural tube defects associated with using DTG at conception in the Tsepamo study has \ndeclined from 0.94% (4 of 426 exposures) to 0.30% (5 of 1683 exposures), the prevalence difference remains statistically \nsignificantly higher than all other ARV drug exposure groups. A further study by the Botswana Ministry of Health and \nthe United States Centers for Disease Control and Prevention (CDC) increased the number of birth outcome surveillance \nsites in Botswana, expanding the estimated coverage of births in Botswana from 72% in the Tsepamo study to 92% of all \nbirths. A",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Updates the evidence on neural tube defects among infants born to women taking DTG at conception, reporting a fall in the Tsepamo study estimate to 0.30% and additional surveillance data from Botswana. It places the absolute risk as very low, notes the role of folate fortification and calls for continued surveillance, and concludes that modelling favours DTG on balance and cost-effectiveness.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-325892/blocks/figure-img-p005-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 5,
      "pageEnd": 5,
      "target": "../images/img-p005-1.webp",
      "narrative": "draft",
      "content": "A photograph of a smiling older woman in a brown hat and purple cardigan carrying a large bundle of green stalks with yellow flowers on her back, tied with a striped cloth across her chest.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-325892/blocks/prose-sec-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "\u0007Box 3: A woman-centred approach",
      "pageStart": 5,
      "pageEnd": 6,
      "target": "../sections/sec-005-box-3-a-woman-centred-approach.md",
      "narrative": null,
      "content": "Woman-centred health services involve an \napproach to health care that consciously adopts \nthe perspectives of women and their families and \ncommunities. This means that health services see \nwomen as active participants in and beneficiaries \nof trusted health systems that respond to women’s \nneeds, rights and preferences in humane and  \nholistic ways (with no coercion). Care is provided  \nin ways that respect a woman’s autonomy in \ndecision-making about her health, and services  \nmust provide information and options to enable \nwomen to make informed choices. The needs and \nperspectives of wome",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes a woman-centred, human rights-based approach to antiretroviral therapy that respects women's autonomy and informed choice. It then covers DTG approval and formulations for children, raltegravir as an option from birth, and the need for twice-daily DTG in people with HIV and TB on rifampicin.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-325892/blocks/prose-sec-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EFV 400 mg in first-line ART",
      "pageStart": 6,
      "pageEnd": 8,
      "target": "../sections/sec-006-efv-400-mg-in-first-line-art.md",
      "narrative": null,
      "content": "The updated systematic review found that EFV 400 mg is \nbetter tolerated than EFV in standard dose (EFV 600 mg), with \nlower risk of treatment discontinuation and severe treatment-\nrelated adverse events. Regimens containing EFV 400 mg and \nEFV 600 mg were comparable for viral suppression, mortality \nand mental and nervous system adverse events.\nEFV 400 mg is available in a smaller pill size and can \npotentially reduce treatment costs compared with EFV 600 \nmg; both are available as generic fixed-dose combinations.\nEFV 400 mg is expected to be safe for pregnant women \nto use, like EFV 600 mg.",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reviews evidence showing efavirenz 400 mg is better tolerated than the 600 mg dose, with similar viral suppression, lower cost and expected safety in pregnancy. It discusses limited data on its use with rifampicin-based TB treatment and its pharmacokinetics in pregnancy. It then introduces the review of DTG for people whose non-DTG first-line regimen has failed, finding DTG generally outperforms protease-inhibitor-based second-line therapy on safety and efficacy.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-325892/blocks/figure-img-p007-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 7,
      "pageEnd": 7,
      "target": "../images/img-p007-1.webp",
      "narrative": "draft",
      "content": "A photograph of a smiling woman, a man and a small child standing on a white backdrop outside a house. The woman holds a sign reading “AIDS treatment for all” and the man a sign reading “Acceptance of all HIV+ people”.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-325892/blocks/table-001",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 1. Preferred and alternative first-line ART regimens",
      "pageStart": 7,
      "pageEnd": 7,
      "target": "../tables/table-1.csv",
      "narrative": "draft",
      "content": "Preferred, alternative and special-circumstance first-line antiretroviral regimens for adults and adolescents, children and neonates, with footnotes on contraception and DTG, EFV pretreatment resistance and age/weight dosing limits.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-325892/blocks/prose-sec-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "DTG in second-line ART",
      "pageStart": 8,
      "pageEnd": 9,
      "target": "../sections/sec-007-dtg-in-second-line-art.md",
      "narrative": null,
      "content": "Taken together with other advantages, including lower \ncost, less potential for drug–drug interactions, lower \npill burden and availability in once-daily fixed-dose \ncombinations, DTG is recommended as the preferred ARV \ndrug for second-line ART among adults, adolescents and \nchildren for whom a non-DTG-based first-line regimen has \nfailed. For those taking a first-line regimen containing DTG \nthat has failed, a boosted PI-containing regimen should be \nused (Table 2).\nTable 2. Preferred and alternative second-line ART regimens\nPopulation\nFailing first-line regimen\nPreferred second-line regimen",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Recommends DTG as the preferred second-line drug for adults, adolescents and children failing non-DTG first-line regimens, and a boosted protease inhibitor for those failing DTG-based first-line therapy. Table 2 lists preferred and alternative second-line regimens by population and failing regimen, with footnotes on dosing and use in children.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-325892/blocks/table-002",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 2. Preferred and alternative second-line ART regimens",
      "pageStart": 8,
      "pageEnd": 8,
      "target": "../tables/table-2.csv",
      "narrative": "draft",
      "content": "Preferred and alternative second-line ART regimens according to the failing first-line regimen, for adults and adolescents and for children and infants.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-325892/blocks/figure-vfig-p009",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 9,
      "pageEnd": 9,
      "target": "../figures/vfig-p009.webp",
      "narrative": "draft",
      "content": "A page render with two columns of text above Figure 1, “Major factors that can influence the transition to DTG”, a three-column diagram with icons. Clinical and epidemiological factors include the percentage of women with HIV of childbearing potential, use of suboptimal first-line regimens, availability of second- and third-line options and pre-treatment NNRTI resistance. Commodities include stocks of EFV and DTG, access to contraception and viral load testing, and availability of fixed-dose and generic formulations. Programme and policy factors include inclusion in national guidelines, supply chain capacity, training of health-care providers, translating the policy to community, and toxicity and pregnancy safety monitoring.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-325892/blocks/prose-sec-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Transition to DTG and EFV 400 mg in national HIV programmes",
      "pageStart": 9,
      "pageEnd": 9,
      "target": "../sections/sec-008-transition-to-dtg-and-efv-400-mg-in-national-hiv.md",
      "narrative": null,
      "content": "national HIV programmes",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A section heading fragment on transitioning national HIV programmes to DTG and efavirenz 400 mg.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-325892/blocks/prose-sec-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Clinical and implementation considerations",
      "pageStart": 9,
      "pageEnd": 12,
      "target": "../sections/sec-009-clinical-and-implementation-considerations.md",
      "narrative": null,
      "content": "considerations\nMultiple suppliers are capable of manufacturing DTG as a \nsingle product and as part of a fixed-dose combination and \nhave already begun expanding capacity to cope with the \nincreased demand. No shortfalls in manufacturing capacity \nare currently anticipated, although countries should \nundertake effective supply planning.\nKenya, Zambia and Zimbabwe have transitioned from EFV \n600 mg to EFV 400 mg, and about 1.7 million people living \nwith HIV are currently receiving TDF + 3TC + EFV 400 mg. \nMore than 25 countries have included regimens containing \nEFV 400 mg in their national gu",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes manufacturing capacity for DTG and progress by countries in adopting efavirenz 400 mg and DTG into guidelines and procurement. It sets out drug–drug interaction cautions, such as with certain anticonvulsants and cation-containing antacids and supplements, and advises a phased transition with buffer stocks. Tables summarize considerations for transitioning adults, adolescents and children who are stable on ART to optimal regimens.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-325892/blocks/figure-img-p010-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 10,
      "pageEnd": 10,
      "target": "../images/img-p010-1.webp",
      "narrative": "draft",
      "content": "A photograph of a woman in a pink dress and a cap sitting on a bed in a room with an orange wall, holding up a small white pill in one hand and a medicine blister pack in the other.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-325892/blocks/table-003",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 3. Considerations for transition to TDF + 3TC + DTG among adults and adolescents",
      "pageStart": 11,
      "pageEnd": 11,
      "target": "../tables/table-3.csv",
      "narrative": "draft",
      "content": "Preferred approaches and comments for moving adults and adolescents to TDF + 3TC + DTG, for people initiating ART (general, pregnant and breastfeeding women, TB coinfection) and for people already on first-line ART (by viral load, clinical status and regimen).",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-325892/blocks/prose-sec-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "considered stable on ART based on national guidelines",
      "pageStart": 12,
      "pageEnd": 12,
      "target": "../sections/sec-010-considered-stable-on-art-based-on-national-guide.md",
      "narrative": null,
      "content": "Current regimen\nWeight\nOptimal regimen  \nfor transition\nConsiderations",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Column headings of a table on transitioning children considered stable on ART: current regimen, weight, optimal regimen and considerations.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-325892/blocks/prose-sec-011",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "AZT + 3TC + NVP",
      "pageStart": 12,
      "pageEnd": 12,
      "target": "../sections/sec-011-azt-3tc-nvp.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-325892/blocks/prose-sec-012",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "AZT + 3TC + EFV",
      "pageStart": 12,
      "pageEnd": 12,
      "target": "../sections/sec-012-azt-3tc-efv.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-325892/blocks/prose-sec-013",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "ABC + 3TC + NVP",
      "pageStart": 12,
      "pageEnd": 12,
      "target": "../sections/sec-013-abc-3tc-nvp.md",
      "narrative": null,
      "content": "<20 kg\nABC + 3TC + LPV/r\nIf stable, children can be transitioned  \nto DTG when they reach 20 kg\n20–30kg\nABC + 3TC + DTG\nIf stable, children can be transitioned to \nTDF + 3TC + DTG when they reach 30 kg\n> 30 kg\nTDF + 3TC + DTG\n–",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Table rows giving weight-based transition options for children currently on abacavir, lamivudine and nevirapine, moving to DTG-based regimens as they reach 20 kg and 30 kg.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-325892/blocks/prose-sec-014",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "ABC + 3TC + EFV",
      "pageStart": 12,
      "pageEnd": 14,
      "target": "../sections/sec-014-abc-3tc-efv.md",
      "narrative": null,
      "content": "<20 kg\nNo change until they reach \n20 kg unless treatment \nfailure occurs\nTransition to optimal regimens for these \nchildren is of value once they reach  \n20 kg and DTG can be used maintaining \nonce-daily administration\n20–30 kg\nABC + 3TC + DTG\nIf stable, children can be transitioned to \nTDF + 3TC + DTG when they reach 30 kg\n> 30 kg\nTDF + 3TC + DTG\n–\nABC + 3TC + LPV/r\nAZT + 3TC + LPV/r\n<20 kg\nNo change until they reach \n20 kg unless treatment \nfailure occurs\nEnsure the use of tablets as soon \nas possible to reduce pill burden. \nTransition from AZT + 3TC + LPV/r \nto ABC + 3TC + LPV/r can also b",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Continues the transition table for children on efavirenz- or lopinavir/ritonavir-based regimens, giving weight-banded options and advice on reducing pill burden. It is followed by the opening references of the policy brief, on DTG, efavirenz and the transition to new antiretrovirals.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-325892/blocks/table-004",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 4. Considerations for transition to optimal ART regimens for children who are considered stable on ART based on national guidelines",
      "pageStart": 12,
      "pageEnd": 12,
      "target": "../tables/table-4.csv",
      "narrative": "draft",
      "content": "For children considered stable on ART, the table gives, by current regimen and weight band (<20 kg, 20–30 kg, >30 kg), the optimal regimen to transition to and related considerations.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-325892/blocks/figure-img-p013-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 13,
      "pageEnd": 13,
      "target": "../images/img-p013-1.webp",
      "narrative": "draft",
      "content": "A photograph of two people with long dark hair standing close together in a doorway of a purple building, behind an open black wrought-iron gate, on a city street.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-325892/blocks/prose-sec-015",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "REFERENCES",
      "pageStart": 14,
      "pageEnd": 16,
      "target": "../sections/sec-015-references.md",
      "narrative": null,
      "content": "13.\t Hill A, Waters L, Pozniak A. Are new antiretroviral treatments \nincreasing the risks of clinical obesity? J Virus Erad. \n2019;5:e45–7.\n14.\t Dugdale CM, Ciaranello AL, Bekker L-G, Stern ME, Myer L, Wood \nR et al. Risks and benefits of dolutegravir-and efavirenz-based \nstrategies for South African women with HIV of child-bearing \npotential: a modeling study. Ann Intern Med. 2019;170:614–25.\n15.\t Phillips AN, Venter F, Havlir D, Pozniak A, Kuritzkes D, Wensing A \net al. Risks and benefits of dolutegravir-based antiretroviral drug \nregimens in sub-Saharan Africa: a modelling study. Lancet HIV",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The remainder of the reference list for the 2019 antiretroviral policy brief, citing studies on weight gain, DTG risk–benefit modelling and spina bifida prevalence, followed by WHO HIV/AIDS department contact details.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    }
  ]
}
